Pharmaceuticals
Japan’s Takeda to buy US cancer drug maker Ariad for $5.20 bn
10 Jan 2017
The deal will give Takeda two innovative precision drugs, including a leukemia drug with sales of $170-180 million last year, and Brigatinib, which could offset any loss of sales due to generic competition to its top-selling blood cancer drug Velcade
.webp)
